We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α-Based Regimens.
- Authors
Muir, A J; Gong, L; Johnson, S G; Lee, M T M; Williams, M S; Klein, T E; Caudle, K E; Nelson, D R
- Abstract
Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-containing regimens based on IFNL3 genotype.
- Subjects
INTERFERON beta-1a; PHARMACOGENOMICS; GUIDELINES; RIBAVIRIN; HEPATITIS C treatment; DECISION making in clinical medicine
- Publication
Clinical Pharmacology & Therapeutics, 2014, Vol 95, Issue 2, p141
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1038/clpt.2013.203